Patent · US Active

Use of aromatic ring drug in inhibiting key transcription factor of malignant melanoma

US11077097B2 · kind B2 · utility

0Cited by

0References

13Claims

0Family size

Assignee

SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES · CN

Inventors

Jing Wang · Taipei, TW
Min Guo · Fremont, US
Pengfei Fang · Shanghai, CN
Biao Yu · Shanghai, CN

Key dates

Filing date	Jun 4, 2018
Grant date	Aug 3, 2021
Priority date	—
Expiry date	Jul 11, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is the use of an aromatic ring drug in inhibiting a key transcription factor of malignant melanoma. In particular, provided is the use of a compound as represented by formula A, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition or preparation. The pharmaceutical composition or preparation is used for: (a) inhibiting a key transcriptional regulatory factor of malignant melanoma, namely MITF (Microphthalmia-associated Transcription Factor); (b) treating MITF-related diseases such as melanoma, pancreatic cancer, skin hypersensitivity and asthma; and (c) regulating physiological activities in which MITF is involved, such as skin whitening. In the formula, each group is as defined in the description.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.